FDMT
4D Molecular Therapeutics, Inc.·Healthcare
9.81
0.305%(−0.03)
Market ClosedLast Updated: — ET
52W L: $2.5652W H: $12.34
FDMT NEWS
defenseworld.net
Apr 3
4D Molecular Therapeutics (NASDAQ:FDMT) versus TransCode Therapeutics (NASDAQ:RNAZ) Head-To-Head Contrast
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk. Insider and Institutional Ownership 99.3% of
defenseworld.net
Mar 31
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) by 55.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,199 shares of the company's stock after selling 367,458 shares during the period. Assenagon Asset Management
defenseworld.net
Mar 20
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up Following Analyst Upgrade
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report)'s stock price gapped up before the market opened on Thursday after Royal Bank Of Canada raised their price target on the stock from $32.00 to $35.00. The stock had previously closed at $8.56, but opened at $9.94. Royal Bank Of Canada currently has an outperform rating
zacks.com
Mar 18
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $0.53 per share. This compares to a loss of $0.9 per share a year ago.
globenewswire.com
Mar 18
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2025 financial results, provided operational highlights and outlined expected upcoming milestones.
globenewswire.com
Mar 16
4DMT to Participate in Upcoming Investor Meetings
EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March.
